A PHYSICIAN’S GUIDE TO CRITICAL NEUROLOGY CONDITIONS
CONTENTS

1. NeurologyLive® Dementia/Alzheimer Disease Clinical Focus Center
2. NeurologyLive® Epilepsy Clinical Focus Center
3. NeurologyLive® Multiple Sclerosis Clinical Focus Center
4. NeurologyLive® Movement Disorders Clinical Focus Center
5. NeurologyLive® Headache and Migraine Clinical Focus Center
6. NeurologyLive® Stroke Clinical Focus Center
7. NeurologyLive® Sleep Medicine Clinical Focus Center
8. NeurologyLive® Neuromuscular Clinical Focus Center
NeurologyLive® Dementia/Alzheimer Disease Clinical Focus Center

NeurologyLive®’s Dementia/Alzheimer Disease Clinical Focus center serves as a resource for clinical news, feature articles, videos, and newly released data pertaining to neurodegenerative diseases. Coverage includes updates from the floor of conferences and annual meetings attended by the world’s most respected neurology thought leaders, as well as video interviews with leading experts in neurological disorders.

This page features breaking news coverage of approvals from the FDA, key takeaways from clinical trials on new and emerging therapies, and notifications of updates to clinical guidelines. The Dementia/Alzheimer Disease Clinical Focus page provides relevant, high-quality resources for practicing neurologists to help improve patient care.

WATCH: COSTANTINO IADECOLA, MD, ON COGNITIVE RESERVE IN ALZHEIMER DISEASE

Costantino Iadecola, MD, discusses the role of cognitive reserve in the pathogenesis of Alzheimer disease.

Click to view the full feature video.

AVANIR REPORTS PHASE 3 DATA OF AVP-786 FOR AGITATION IN ALZHEIMER DISEASE

Avanir Pharmaceuticals has released top-line results from TRIAD-1 (NCT02442765), the first of 2 phase 3 studies of the investigational therapy AVP-786 for treating moderate-to-severe agitation in patients with Alzheimer-related dementia. Results demonstrated a significant improvement on the primary end point—change in the Cohen-Mansfield Agitation Inventory—for 1 of the 2 doses studied.

Click to read the full article.

DRAWING ON BLOOD FOR BIOMARKERS OF ALZHEIMER DISEASE

Results from new reports of potential biomarkers for Alzheimer disease in the blood suggest progress in the search for signals of the disease in a more accessible medium than cerebrospinal fluid. However, challenges exist, and the studies marked just tentative progress in the view of experts recently invited to assess developments in the field.

Click to read the full article.
NeurologyLive® Epilepsy Clinical Focus Center

NeurologyLive®’s Epilepsy Clinical Focus center provides a hub for the latest clinical information pertaining to seizure disorders, with articles and videos closely covering the robust pipeline of new and emerging epilepsy therapies, as well as data from recent and ongoing clinical trials. It provides a wealth of information and news from relevant conferences and annual meetings hosted by neurological associations and includes pivotal coverage right from the floor.

Among its offerings are videos featuring interviews with key opinion leaders and experts in epilepsy that focus on best practices and key methods for recognizing and treating epilepsy, including complex cases, applying novel therapies, and addressing the challenges of treating the disease.

Q&A: DISCUSSING THE RISK OF SUDDEN UNEXPECTED DEATH IN EPILEPSY WITH PATIENTS AND CAREGIVERS

Jeffrey Buchhalter, MD, a pediatric epileptologist and an adjunct professor of pediatrics at the University of Calgary in Alberta, Canada, discusses SUDEP and how to best educate and inform patients and caregivers about their individual risk.

Click to read the full interview.

WHAT YOU NEED TO KNOW ABOUT CANNABIDIOL FOR RARE FORMS OF EPILEPSY

This guide includes key details about cannabidiol (Epidiolex, GW Pharmaceuticals) for the treatment of 2 rare types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.

Click to read the full interview.

WATCH: J. ERIC PINA-GARZA, MD, ON INCREASING EPILEPSY AWARENESS

For J. Eric Piña-Garza, MD, the director of pediatric epilepsy at Centennial Children’s Hospital, one of the biggest challenges in epilepsy right now involves raising awareness of the disease. Other conditions, such as breast cancer, garner much more traction in funding and awareness despite affecting fewer patients each year than epilepsy.

Click to view the full feature video.
NeurologyLive® Multiple Sclerosis Clinical Focus Center

NeurologyLive®’s Multiple Sclerosis Clinical Focus center offers the latest clinical news and expert insights related to this disabling disease of the central nervous system. Content includes video interviews with multiple sclerosis experts and key opinion leaders in neurology sharing insights on new and emerging therapies and management techniques.

This page offers information regarding current strategies for multiple sclerosis treatment, as well as emerging data on therapeutic options being presented at major medical conferences and gaining traction in the scientific literature.

WATCH: STEPHEN KRIEGER, MD, ON RISK MITIGATION IN MULTIPLE SCLEROSIS

SIPONIMOD CLEARED FOR TREATMENT OF SECONDARY PROGRESSIVE MS

The FDA has approved siponimod (Mayzent, Novartis), the first treatment for patients with active secondary progressive multiple sclerosis (SPMS) in more than a decade. The approval was granted based on data from the EXPAND trial, the largest phase 3 assessment of its kind, including more than 1600 patients with SPMS. It ultimately showed that 3-month confirmed disability progression was reduced by 21% ($P = .013$).

Click to read the full article.

Stephen Krieger, MD, explains that although the multiple sclerosis treatment landscape is vast, a major factor in prescribing comes down to how the medicines can be used as safely as possible.

Click to view the full feature video.

WHAT YOU NEED TO KNOW ABOUT FINGOLIMOD FOR TREATING RELAPSING MULTIPLE SCLEROSIS

This guide offers key details about fingolimod (Gilenya, Novartis) for the treatment of relapsing multiple sclerosis in adults and children, including dosing, pharmacology, contraindications, and costs.

Click to read the overview.
NeurologyLive® Movement Disorders Clinical Focus Center

NeurologyLive®’s Movement Disorder Clinical Focus center provides a resource for current clinical information, with articles covering updates from the robust pipeline of novel therapies in development, as well as the latest data from all phases of clinical trials in the space. It also serves as an information hub for conferences and annual meetings hosted by neurological societies and associations on the latest advances in Parkinson disease, Tardive dyskinesia, Huntington disease, and more.

This resource includes numerous interviews with movement disorder specialists covering best practices and key methods for treating complex cases, using the newest therapies, and examining treatment challenges.

WATCH: PETER LEWITT, MD, DISCUSSES THE THERAPY PIPELINE IN PARKINSON DISEASE

The director of the Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital in Detroit, Michigan, sat down with NeurologyLive® to discuss the therapies being developed for Parkinson disease and the enhancement of the clinical understanding of the disease.

Click to view the full feature video.

MOBILE HEALTH TECH MUST BE INTEGRATED INTO PARKINSON DISEASE CARE, MDS TASK FORCE SAYS

According to the Movement Disorder Society Task Force on Technology, the development and implementation of mobile health technology into routine use in the care of Parkinson disease is now necessary, and the group has laid out a road map of 4 recommendations.

Click to read the full article.

WHAT YOU NEED TO KNOW ABOUT AMANTADINE FOR PARKINSON DISEASE

This guide offers key details about amantadine (Osmolex ER, Osmotica Pharmaceuticals) for the treatment of Parkinson disease and drug-induced extrapyramidal reactions in adults, including dosing, pharmacology, contraindications, and patient counseling.

Click to read the overview.
WHAT YOU NEED TO KNOW ABOUT ERENUMAB FOR PREVENTIVE TREATMENT OF MIGRAINE

This guide provides key details about erenumab-aooe (Aimovig, Amgen/Novartis) for the preventive treatment of migraine in adults, including dosing, pharmacology, clinical studies, and costs.

FDA UPDATES ERENUMAB LABEL TO INCLUDE HYPERSENSITIVITY RISK

The FDA added a safety-related label change to erenumab (Aimovig, Amgen/Novartis) to include a contraindication for patients with serious hypersensitivity to erenumab or any of the excipients because of the risk of anaphylaxis and angioedema.

WATCH: JESSICA AILANI, MD, ON CONTINUING TO IMPROVE ACUTE MIGRAINE CARE

The director of the MedStar Georgetown University Hospital Headache Center discusses the development of acute care options for patients with migraine to improve their quality of life and the management of their condition.

WHAT YOU NEED TO KNOW ABOUT ERENUMAB FOR PREVENTIVE TREATMENT OF MIGRAINE

This guide provides key details about erenumab-aooe (Aimovig, Amgen/Novartis) for the preventive treatment of migraine in adults, including dosing, pharmacology, clinical studies, and costs.
NeurologyLive® Stroke Clinical Focus Center

*NeurologyLive*’s Stroke Clinical Focus center serves as a hub of vital information and news that can benefit both neurologists at the point of care and those focused on identifying best practices and new treatment strategies through research. This page provides the latest clinical information, covering data from the most recent trials and studies in the space.

Visitors to the Stroke Clinical Focus center can hear from the most respected neurology thought leaders and experts specializing in stroke. Conference coverage includes the latest research being conducted, and experts discuss topics such as treating complex cases and using the newest therapies and procedures.

**WATCH: ASHER J. ALBERTSON, MD, PHD, ON GETTING INTERVENTIONS TO STROKE PATIENTS**

In stroke, much of the research focuses on better understanding the mechanisms of the condition and the subcortical structures of the brain with the long-term hope of improving stroke recovery. Asher J. Albertson, MD, PhD, a neurocritical care fellow at Washington University School of Medicine in St. Louis, is doing some of that work.

[Click to view the full feature video.](#)

**FDA WARNS OF STROKE, ARTERIAL DISSECTION WITH ALEMTUZUMAB FOR MS**

The FDA issued a warning regarding the occurrence of rare but serious cases of stroke and arterial lining tears in the head and neck of patients with multiple sclerosis (MS) shortly after being treated with alemtuzumab (Lemtrada, Sanofi Genzyme). According to the agency, these issues could lead to permanent disability and even death.

[Click to read the full article.](#)

**TELESTROKE OFFERS OPPORTUNITIES, BUT CHALLENGES PERSIST**

The argument in favor of stroke telemedicine, or telestroke—the services in which neurologists offer remote treatment to patients who have had a stroke—has been growing. Many supporters of telestroke point to its ability to improve patient outcomes, although implementing these systems requires overcoming a few obstacles.

[Click to read the full article.](#)
NeurologyLive® Sleep Medicine Clinical Focus Center

Content found within NeurologyLive™’s Sleep Medicine Clinical Focus center offers the latest and most valuable information on emerging therapies for sleep disorders. Articles include relevant updates from the floor of the most notable neurology conferences and annual meetings, as well as video interviews with leading experts in neurology, especially those focused on the treatment of narcolepsy and obstructive sleep apnea.

Lack of sleep has proved to be damaging to physical, mental, and emotional health, and this page’s content—breaking news coverage of FDA approvals, key takeaways from recent clinical trials of new and emerging therapies, and notifications of updates to clinical guidelines—aims to dramatically improve patient care.

WATCH: RICARDO OSORIO, MD, ON THE RELATIONSHIP BETWEEN SLEEP AND ALZHEIMER DISEASE

Q&A: RESTLESS LEG SYNDROME WARRANTS MORE ATTENTION, EXPERT SAYS

Current estimates suggest that restless leg syndrome (RLS) affects about 10% of the population, and the National Sleep Foundation says that 94% of cases are still either undiagnosed or misdiagnosed. To provide additional insight into RLS, a debilitating neurological disorder that warrants more attention, NeurologyLive™ spoke with Daniel Lee, MD, medical director at Baptist Health Neurology and clinical professor at the University of Kentucky College of Medicine.

Click to read the full interview.

SOLRIAMFETOL WINS FDA APPROVAL FOR EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA

The FDA has approved solriamfetol (Sunosi, Jazz Pharmaceuticals) for the treatment of excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea. The dual-acting dopamine and norepinephrine reuptake inhibitor is approved for narcolepsy in once-daily 75- and 150-mg doses and in obstructive sleep apnea in once-daily 37.5-, 75-, and 150-mg doses.

Click to read the full article.
WHAT YOU NEED TO KNOW ABOUT SUBCUTANEOUS IMMUNOGLOBULIN FOR THE TREATMENT OF CIDP AND PI

This guide includes key details about subcutaneous immunoglobulin (Hizentra, CSL Behring) in the treatment of chronic inflammatory demyelinating polyneuropathy and primary immunodeficiency, including dosing and administration, contraindications, adverse reactions, and costs.

GENETIC TARGETS INVIGORATE RESEARCH FOR DUCHENNE MUSCULAR DYSTROPHY

With a number of gene therapies and exon-skipping therapies being evaluated in clinical trials, clinicians treating muscular dystrophies have begun to discuss the potential implications of using these therapies for patients with Duchenne muscular dystrophy.

WATCH: RALPH KERN, MD, MHSC, ON THE STATE OF THERAPIES FOR ALS

Ralph Kern, MD, MHSc, discusses the current landscape of therapies for amyotrophic lateral sclerosis (ALS), including excitement surrounding the study of new biologics in this area.